4 terminated, 3 not yet recruiting, 3 recruiting, 1 withdrawn. 6 Phase 2, 2 Phase 1, 2 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Not yet recruiting 2, Terminated 2, Recruiting 1, Withdrawn 1 |
| Phase 1 | 2 | Terminated 2 |
| Phase 3 | 2 | Recruiting 2 |
| Not applicable | 1 | Not yet recruiting 1 |
Follow NSCLC (Non-small Cell Lung Carcinoma): new trials by email Literature Review of NSCLC (Non-small Cell Lung Carcinoma) trials Research Report on NSCLC (Non-small Cell Lung Carcinoma)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors. Signatera Genome ultra-sensitive ctDNA blood test - NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer) | Not applicable | Not yet recruiting | Natera, Inc. | 920 | 2027-01-01 | 2026-10-27 |
| Local Consolidative Therapy Versus Maintenance Immunotherapy After First-Line Chemoimmunotherapy in Metastatic NSCLC Immediate Local Consolidative Therapy (LCT) - NSCLC (Non-small Cell Lung Carcinoma) | Phase 2 | Not yet recruiting | Guangdong Provincial People's Hospital | 117 | 2026-10-08 | 2026-09-25 |
| Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma Firmonertinib, Definitive Thoracic Radiotherapy - NSCLC (Non-small Cell Lung Carcinoma), Stage III | Phase 2 | Recruiting | Hunan Cancer Hospital | 15 | 2026-06-22 | 2026-07-08 |
| Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI Zorifertinib Plus Intra-Ommaya CSF Chemotherapy - NSCLC (Non-small Cell Lung Carcinoma), Leptomeningeal Metastasis | Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 38 | 2026-05-30 | 2026-04-24 |
| Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC Nivolumab 40mg, Cisplatin, Carboplatin, Pemetrexed, Gemcitabine, Paclitaxel, Docetaxel - NSCLC (Non-small Cell Lung Carcinoma), First Line Therapy | Phase 3 | Recruiting | Dr Arvindran A/L Alaga | 123 | 2025-05-19 | 2025-07-03 |
| Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) daraxonrasib, docetaxel - NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer | Phase 3 | Recruiting | Revolution Medicines, Inc. | 590 | 2025-05-06 | 2026-11-06 |
| A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer BG-60366 - Non-Small Cell Lung Cancer, Lung Cancer | Phase 1 | Terminated | BeOne Medicines | 33 | 2024-12-05 | 2026-05-22 |
| A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma Epacadostat, Atezolizumab - NSCLC (Non-small Cell Lung Carcinoma), UC (Urothelial Cancer) | Phase 1 | Terminated | Incyte Corporation | 29 | 2015-01-27 | 2026-04-20 |
| Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations Itacitinib, erlotinib, placebo - Solid Tumors and Hematologic Malignancy, NSCLC (Non-small Cell Lung Carcinoma) | Phase 2 | Withdrawn | Incyte Corporation | 2014-12-01 | 2019-03-08 | |
| Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer Itacitinib, docetaxel - NSCLC (Non-small Cell Lung Carcinoma) | Phase 2 | Terminated | Incyte Corporation | 9 | 2014-09-24 | 2026-04-21 |
| Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer Ruxolitinib, Placebo, Pemetrexed - NSCLC (Non-small Cell Lung Carcinoma) | Phase 2 | Terminated | Incyte Corporation | 76 | 2014-02-11 | 2018-02-13 |
Carcinoma, Non-Small-Cell Lung (11) · Lung Neoplasms (2) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1) · Hematologic Neoplasms (1) · Melanoma (1) · Meningeal Carcinomatosis (1)
Bronchial Neoplasms (11) · Carcinoma, Bronchogenic (11) · Lung Diseases (11) · Neoplasms (11) · Neoplasms by Site (11) · Respiratory Tract Diseases (11) · Respiratory Tract Neoplasms (11) · Thoracic Neoplasms (11) · Lung Neoplasms (9) · Adenocarcinoma (1) · Carcinoma (1) · Central Nervous System Neoplasms (1) · Colonic Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1)
Docetaxel (3) · Cisplatin (2) · INCB039110 (2) · Pemetrexed (2) · itacitinib (2) · Carboplatin (1) · Erlotinib Hydrochloride (1) · Gemcitabine (1) · Nivolumab (1) · Paclitaxel (1) · Radiotherapy (1) · aflutinib (1) · atezolizumab (1) · epacadostat (1) · ruxolitinib (1)
Incyte Corporation (4) · BeOne Medicines (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Dr Arvindran A/L Alaga (1) · Guangdong Provincial People's Hospital (1) · Hunan Cancer Hospital (1) · Natera, Inc. (1) · Revolution Medicines, Inc. (1)
United States (6) · China (4) · Australia (2) · Italy (2) · New Zealand (2) · South Korea (2) · Spain (2) · Belgium (1) · France (1) · Germany (1) · Hong Kong (1) · Ireland (1) · Japan (1) · Malaysia (1) · Netherlands (1)
Amit Pande, M.D. (1) · Gerard T Kennealey, MD (1) · Gerard T. Kennealey, M.D. (1) · Glenn Hanna, MD (1) · Hiroomi Tada, MD (1) · Huai Liu, M.Med. (1) · Wan Jinghai (1) · Xingxiang Pu, M.D. (1)